Flowers for Algernon: How metacognition affects quality of life in schizophrenia. Structural equation modeling with the FACE-SZ cohort.

Background And Hypothesis: We examined the association between metacognitive performance, functioning, and quality of life (QoL) in schizophrenia using structural equation model analyses.

Study Design: A sample of 249 participants was assessed for symptoms, functioning, QoL, and both objective and subjective cognitive performance. Metacognitive performance was defined as the adequation between objective and subjective measures of cognitive performance.

Exploring the Association Between Residual Mood Symptoms and Self-Reported Side Effects in the Euthymic Phase of Bipolar Disorders: A Cross-Sectional Network Analysis.

Bipolar disorders (BD) are characterized by mood symptoms that can worsen medication side effects. We aimed to study the association between residual mood signs and self-reported side effects in the euthymic phase of BD. We assessed residual mood signs using the Montgomery-Asberg Depression Rating scale (MADRS) and Young Mania Rating scale (YMRS) and self-reported side effects using the Patient-Rated Inventory of Side Effects (PRISE-M) for 880 males and 1369 females with BD.

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia.